IFF Introduces ENVIROCAP™, a Breakthrough Scent Delivery Technology for Fabric Care
24.7.2025 12:00:00 CEST | Business Wire | Press Release
IFF (NYSE: IFF), a global leader in flavors, fragrances, and biosciences, has launched ENVIROCAP™ — its newest sustainable scent delivery system designed for the future of fabric care. Developed by IFF’s world-class scientists and fragrance delivery experts, ENVIROCAP™ sets a new standard in innovation: it is fully ECHA-compliant¹, biodegradable² and vegan-suitable³. At the heart of this technology is a proprietary biopolymer that delivers long-lasting fragrance while reducing environmental impact. ENVIROCAP™ not only meets the rising consumer demand for sustainability — it redefines the standard for performance and cost-efficiency.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250724026783/en/
“The launch of ENVIROCAP™ marks a bold new chapter in fragrance encapsulation,” said Ana Paula Mendonça, president, IFF Scent. “In 2005, IFF revolutionized laundry care with scent bursts that brought joy throughout the day. Now, we’re leveraging our leading nature-based bio innovation capabilities to redefine the power of scent technology in laundry — delivering superior sustainability and performance without compromise. With ENVIROCAP™, we aim to support our customers in innovating and bringing true differentiation through elevated sensory impact and sustainability, while delighting consumers with memorable scent experiences.”
The development of ENVIROCAP™ is rooted in IFF’s deep understanding of the consumer’s laundry care journey — from the moment of purchase to the emotional “moment of truth” when freshly washed clothes are experienced for the first time. Around the world, consumers are increasingly seeking sustainable choices and expect brands to take responsibility for designing products with the environment in mind. ENVIROCAP™ directly answers this call. It delivers an uplifting, long-lasting scent experience that enhances freshness from wash to wear — while aligning with the growing demand for eco-friendly, high-performing and value-driven fabric care solutions.
ENVIROCAP™ also allows perfumers great olfactive freedom to harness the virtually limitless possibilities offered by IFF’s extensive fragrance ingredient portfolio. From sparkling citrus to joyful fruity or sensual floral notes and beyond, ENVIROCAP™ works across all stages of the laundry experience — making joy with scent, one laundry cycle at a time.
Learn more about IFF’s delivery systems and encapsulation technologies here.
(1) | Regulation (EU) 2023/2055 of 25 September 2023 amending Annex XVII to EU REACH Regulation (Regulation (EC) No 1907/2006) as regards synthetic polymer microparticles, | |
(2) | According to Biodegradability rules as outlined in the Appendix 15 of the EU Microplastics Restriction, | |
(3) | According to the criteria of the Vegan Society | Certificate available on demand | |
(4) | Mintel, The Future of Fabric Care, 2024 |
Welcome to IFF
At IFF (NYSE: IFF), we make joy through science, creativity and heart. As the global leader in flavors, fragrances, food ingredients, health and biosciences, we deliver groundbreaking, sustainable innovations that elevate everyday products—advancing wellness, delighting the senses and enhancing the human experience.Learn more at iff.com, LinkedIn, Instagram and Facebook.
©2025 International Flavors & Fragrances Inc. IFF, the IFF Logo, and all trademarks and service marks denoted with ™, SM or ® are owned by IFF or affiliates of IFF unless otherwise noted. All Rights Reserved.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250724026783/en/
Contacts
Judith Gross
Head of Communications and Branding
IFF Scent
media.request@IFF.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom